Orchestra BioMed to Showcase Breakthrough Hypertension Therapy at R&D Day

Orchestra BioMed Holdings

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will host an in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024, at 10:00 AM ET. This event will provide detailed insights into the company’s lead program, atrioventricular interval modulation (AVIM) therapy.

The event aims to address the pressing need for effective treatment options for uncontrolled hypertension, particularly in patients who require pacemakers and other older high-risk individuals. AVIM therapy promises to fill this gap by leveraging a unique mechanism of action supported by both clinical and non-clinical data.

Orchestra BioMed plans to present a wealth of existing clinical evidence from its MODERATO I and II studies. These studies have shown promising results, laying the groundwork for the upcoming BACKBEAT global pivotal study. The design and rationale behind this pivotal study will be a focal point of the presentations.

In addition to insights from Orchestra BioMed’s management, attendees will hear from esteemed physicians who are leaders in the field of cardiology. Notable speakers include:

Dr. David Kandzari, Chief of the Piedmont Heart Institute and Cardiovascular Service Line, Director of Interventional Cardiology, and Chief Scientific Officer for Piedmont Healthcare in Atlanta, Georgia. Dr. Kandzari is also a co-principal investigator on the BACKBEAT global pivotal study. He is a renowned expert in cardiovascular disease, peripheral arterial disease, and interventional cardiology. With national and international leadership roles in clinical trials, Dr. Kandzari has significantly contributed to advancements in cardiovascular treatment. His work includes authoring over 400 studies and delivering more than 800 lectures worldwide. He has consistently been recognized as one of Atlanta’s Top Doctors by Atlanta Magazine from 2011 to 2024 and is ranked among the top 1% of cardiologists by U.S. News & World Report.

READ:  Profero Unveils Bold Rebranding to Signal New Era of Growth

Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System. He also holds the Leona M. and Harry B. Helmsley Charitable Trust Professorship in Medicine in Cardiac Electrophysiology at the Icahn School of Medicine at Mount Sinai and serves as a Clinical Steering Committee Advisor for the BACKBEAT global pivotal study. Dr. Reddy is a leading cardiac electrophysiologist known for his pioneering work in developing advanced therapies for cardiac arrhythmias. His research has driven significant changes in how cardiac patients are treated. Notably, in 2014, he implanted the world’s first miniature leadless pacemaker in a patient’s heart at The Mount Sinai Hospital.

Following the formal presentations, attendees will have the opportunity to engage in a live question and answer session. This will allow for deeper exploration of the presented topics and foster a collaborative atmosphere for discussing the future of hypertension treatment.

Revolutionizing Hypertension Treatment: AVIM Therapy’s Potential Impact

This R&D day is crucial for Orchestra BioMed as it seeks to highlight the potential impact of AVIM therapy. Uncontrolled hypertension remains a major health challenge globally, contributing to severe complications such as heart attacks and strokes. Effective treatment options are limited, especially for patients already dealing with complex conditions requiring pacemakers.

The introduction of AVIM therapy could revolutionize the management of hypertension in these high-risk groups. By stabilizing blood pressure through innovative modulation techniques, the therapy offers hope for improved patient outcomes and quality of life. Additionally, success in the BACKBEAT pivotal study could pave the way for broader adoption and regulatory approval, potentially transforming standards of care in cardiology.

READ:  Environmental Tectonics Corporation Forecasts Promising Future After Reporting Strong Fiscal 2024 Results

For Orchestra BioMed, these developments represent significant progress in their mission to deliver breakthrough medical technologies. The company’s focus on addressing unmet medical needs through innovative solutions positions it as a key player in the life sciences sector.

In summary, the upcoming R&D day will provide critical insights into AVIM therapy and its potential to address a significant medical need. With presentations from leading experts and robust clinical evidence, Orchestra BioMed aims to showcase its commitment to advancing cardiovascular treatment and improving patient outcomes.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.